In microdissected ductal carcinoma in situ, HER-2/neu amplification, but not p53 mutation, is associated with high nuclear grade and comedo histology.
BACKGROUND
HER-2/neu and p53 are two molecular markers that have been the focus of investigation in patients with invasive breast carcinoma. However, most of the published data have relied on immunohistochemical detection of the proteins as a surrogate marker of the underlying genetic alterations, a detection method that often gives variable results due to technical factors. In addition, there are limited data documenting HER-2/neu amplification and p53 mutations in the various histologic subtypes of ductal carcinoma in situ (DCIS). The authors evaluated a series of microdissected, pure DCIS lesions comprising a spectrum of morphologic subtypes (comedo, micropapillary, papillary, cribriform, and solid) and their corresponding normal breast tissue for genetic aberrations in HER-2/neu and p53.


METHODS
HER-2/neu amplification was determined by differential polymerase chain reaction, and p53 mutations were identified by single-strand conformation polymorphism analysis.


RESULTS
HER-2/neu amplification was identified in 12 of 30 DCIS samples (40%), and p53 mutations were identified in 6 of 30 DCIS samples (20%). The genetic alterations were not present in any of the normal breast tissue samples. HER-2/neu amplification occurred predominantly in the comedo subtype (69% vs. 18% of the noncomedo subtype; P = 0.008) and in lesions of high nuclear grade (63% vs. 14% of low grade; P = 0.01). There was no difference in the frequency of p53 mutations among the subtypes or between low grade and high grade lesions. No correlation between the presence of the two genetic alterations was observed.


CONCLUSIONS
The presence of HER-2/neu amplification, but not p53 mutations, correlates with histologic subtype and nuclear grade. The relatively frequent occurrence of HER-2/neu amplification and p53 mutations in DCIS tissue and their absence in normal breast tissue suggest that these genetic aberrations are important early in breast duct carcinogenesis.
Ho
G H
GH
Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.
Calvano
J E
JE
Bisogna
M
M
Borgen
P I
PI
Rosen
P P
PP
Tan
L K
LK
Van Zee
K J
KJ
D001943:Breast Neoplasms / Q000235:genetics* / Q000473:pathology / Q000601:surgery; D002278:Carcinoma in Situ / Q000235:genetics* / Q000473:pathology / Q000601:surgery; D018270:Carcinoma, Ductal, Breast / Q000235:genetics* / Q000473:pathology / Q000601:surgery; D002467:Cell Nucleus / Q000473:pathology; D004273:DNA, Neoplasm / Q000235:genetics; D005784:Gene Amplification; D018734:Genes, erbB-2 / Q000235:genetics*; D016158:Genes, p53 / Q000235:genetics*; D005819:Genetic Markers / Q000235:genetics; D006801:Humans; D009154:Mutation; D010641:Phenotype; D016133:Polymerase Chain Reaction / Q000379:methods; D018807:Polymorphism, Single-Stranded Conformational
D004273:DNA, Neoplasm; D005819:Genetic Markers